Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berotralstat long-term access study for hereditary angioedema
2020-004230-37Phase 3Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Number and proportion of subjects with a treatment-related TEAE. Started Apr 2021; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2020-004230-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004230-37.